<strong>Introduction: </strong>A shoulder mass revealing metastatic prostate cancer is very rare. We report a case of metastatic prostate cancer diagnosed on a shoulder mass and treated with analgesic radi...<strong>Introduction: </strong>A shoulder mass revealing metastatic prostate cancer is very rare. We report a case of metastatic prostate cancer diagnosed on a shoulder mass and treated with analgesic radiotherapy and chemotherapy and androgen deprivation therapy (ADT).<strong> Observations:</strong> A 66 years old patient was referred for a painful right shoulder mass whose biopsy and pathological examination found a Gleason 8 (4 + 4) moderately differentiated adenocarcinoma. The PSA level was 508.52 ng/ml. The patient was treated with analgesic radiotherapy on the right shoulder and chemo-hormonal therapy. At 2 years follow-up, the disease was well controlled. <strong>Conclusion:</strong> A shoulder mass revealing metastatic prostate cancer is not common. Local treatment of the symptomatic metastasis while continuing chemotherapy and ADT improves the quality of life.展开更多
<strong>Context:</strong> <span><span><span><span><span style="font-family:""><span style="font-family:Verdana;">Technological advances have imp...<strong>Context:</strong> <span><span><span><span><span style="font-family:""><span style="font-family:Verdana;">Technological advances have improved the toxicities of radiotherapy. We are evaluating the 3D technique in prostate cancer. </span><b><span style="font-family:Verdana;">Materials and Methods:</span></b><span style="font-family:Verdana;"> Retrospective study from January 2015 to December 2015 with 29 files. Survival was calculated by Kaplan-Meier method. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">We collected 29 patient records over the study period. The median age was 75 years with the following extremes: 54 years and 83 years. The median PSA level was 12 ng/ml with a range of 3.05 to 79 ng/ml. Gleason score analysis showed 6 patients (20.69%) with a score of 6 (3 + 3), 23 patients (79.31%) with a score of 7 including 12 patients (41.38%) with grade 3 and 11 patients (37.93%) with grade 4. The median dose delivered was 74 Gy, with a mean dose of 73.79 Gy and extremes of 70 Gy for the minimum and 76 Gy for the maximum. Hormone therapy was combined with radiotherapy in 17 patients (58.62%). Sev</span><span style="font-family:Verdana;">en patients (24.14%) had grade 1 acute bladder toxicity and one patient</span><span style="font-family:Verdana;"> (3.45%) </span><span style="font-family:Verdana;">had grade 2 acute toxicity. Late bladder toxicity was grade 1 in 5 patients</span><span style="font-family:Verdana;"> (17.24%), grade 2 in 3 patients (10.34%) and grade 3 in 1 patient (3.45%). </span><span style="font-family:Verdana;">Late rectal toxicity, grade 2 in 3 patients (10.34%), grade 3 in 1 patient, was noted. Overall survival at 2 years was 100% and 89.65% at 5 years. Relapse-free </span><span><span style="font-family:Verdana;">survival at 2 years was 82.76% and 62.07% at 5 years. There were 3 deaths (10.34%) of which only one was related to prostate cancer. </span><b><span style="font-family:Verdana;">Conclusion:</span></b></span></span></span><展开更多
<strong>Background:</strong><span style="font-family:""><span style="font-family:Verdana;"> The therapeutic standard for oligoprogressive prostate cancer resistant to c...<strong>Background:</strong><span style="font-family:""><span style="font-family:Verdana;"> The therapeutic standard for oligoprogressive prostate cancer resistant to castration is second-generation hormone therapy. This systemic treatment is expensive. There are oligoprogressive lesions accessible to radiotherapy. </span><b><span style="font-family:Verdana;">Objectives:</span></b><span style="font-family:Verdana;"> To study the impact of radiotherapy of oligoprogressive </span><span><span style="font-family:Verdana;">lesions on the implementation of second generation hormone therapy. </span><b><span style="font-family:Verdana;">Pa</span></b></span><b><span style="font-family:Verdana;">t</span><span style="font-family:Verdana;">ients and Methods:</span></b><span style="font-family:Verdana;"> A retrospective study from 2012 to 2020 was carried</span><span style="font-family:Verdana;"> out. All patients with oligoprogressive prostate cancer who had received radiotherapy on one or more lesions in progression were collated. Survival was calculated using the Kaplan-Meier method. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> 8 patients were treated with stereotactic and conformational radiotherapy between August 2012 and August 2020 in the context of oligoprogressive prostate cancer resistant to castration. The median age at diagnosis of oligoprogression was 73 years with a median PSA level of 3.11 ng/ml. Nine lesions were diagnosed with PET scan PSMA. All the lesions were treated by radiotherapy with different regimens. After a median follow-up of 12.5 months, 7 patients showed a biochemical response to treatment with a median decrease in PSA of 67%. The median survival without clinical or biochemical progression was 7 months. The median survival without the need for further systemic treatment was 9 months. During the follow-up period, six patients received second-generation hormone therapy to treat their relapse, and the other two showed no clinical or biochemical展开更多
文摘<strong>Introduction: </strong>A shoulder mass revealing metastatic prostate cancer is very rare. We report a case of metastatic prostate cancer diagnosed on a shoulder mass and treated with analgesic radiotherapy and chemotherapy and androgen deprivation therapy (ADT).<strong> Observations:</strong> A 66 years old patient was referred for a painful right shoulder mass whose biopsy and pathological examination found a Gleason 8 (4 + 4) moderately differentiated adenocarcinoma. The PSA level was 508.52 ng/ml. The patient was treated with analgesic radiotherapy on the right shoulder and chemo-hormonal therapy. At 2 years follow-up, the disease was well controlled. <strong>Conclusion:</strong> A shoulder mass revealing metastatic prostate cancer is not common. Local treatment of the symptomatic metastasis while continuing chemotherapy and ADT improves the quality of life.
文摘<strong>Context:</strong> <span><span><span><span><span style="font-family:""><span style="font-family:Verdana;">Technological advances have improved the toxicities of radiotherapy. We are evaluating the 3D technique in prostate cancer. </span><b><span style="font-family:Verdana;">Materials and Methods:</span></b><span style="font-family:Verdana;"> Retrospective study from January 2015 to December 2015 with 29 files. Survival was calculated by Kaplan-Meier method. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">We collected 29 patient records over the study period. The median age was 75 years with the following extremes: 54 years and 83 years. The median PSA level was 12 ng/ml with a range of 3.05 to 79 ng/ml. Gleason score analysis showed 6 patients (20.69%) with a score of 6 (3 + 3), 23 patients (79.31%) with a score of 7 including 12 patients (41.38%) with grade 3 and 11 patients (37.93%) with grade 4. The median dose delivered was 74 Gy, with a mean dose of 73.79 Gy and extremes of 70 Gy for the minimum and 76 Gy for the maximum. Hormone therapy was combined with radiotherapy in 17 patients (58.62%). Sev</span><span style="font-family:Verdana;">en patients (24.14%) had grade 1 acute bladder toxicity and one patient</span><span style="font-family:Verdana;"> (3.45%) </span><span style="font-family:Verdana;">had grade 2 acute toxicity. Late bladder toxicity was grade 1 in 5 patients</span><span style="font-family:Verdana;"> (17.24%), grade 2 in 3 patients (10.34%) and grade 3 in 1 patient (3.45%). </span><span style="font-family:Verdana;">Late rectal toxicity, grade 2 in 3 patients (10.34%), grade 3 in 1 patient, was noted. Overall survival at 2 years was 100% and 89.65% at 5 years. Relapse-free </span><span><span style="font-family:Verdana;">survival at 2 years was 82.76% and 62.07% at 5 years. There were 3 deaths (10.34%) of which only one was related to prostate cancer. </span><b><span style="font-family:Verdana;">Conclusion:</span></b></span></span></span><
文摘<strong>Background:</strong><span style="font-family:""><span style="font-family:Verdana;"> The therapeutic standard for oligoprogressive prostate cancer resistant to castration is second-generation hormone therapy. This systemic treatment is expensive. There are oligoprogressive lesions accessible to radiotherapy. </span><b><span style="font-family:Verdana;">Objectives:</span></b><span style="font-family:Verdana;"> To study the impact of radiotherapy of oligoprogressive </span><span><span style="font-family:Verdana;">lesions on the implementation of second generation hormone therapy. </span><b><span style="font-family:Verdana;">Pa</span></b></span><b><span style="font-family:Verdana;">t</span><span style="font-family:Verdana;">ients and Methods:</span></b><span style="font-family:Verdana;"> A retrospective study from 2012 to 2020 was carried</span><span style="font-family:Verdana;"> out. All patients with oligoprogressive prostate cancer who had received radiotherapy on one or more lesions in progression were collated. Survival was calculated using the Kaplan-Meier method. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> 8 patients were treated with stereotactic and conformational radiotherapy between August 2012 and August 2020 in the context of oligoprogressive prostate cancer resistant to castration. The median age at diagnosis of oligoprogression was 73 years with a median PSA level of 3.11 ng/ml. Nine lesions were diagnosed with PET scan PSMA. All the lesions were treated by radiotherapy with different regimens. After a median follow-up of 12.5 months, 7 patients showed a biochemical response to treatment with a median decrease in PSA of 67%. The median survival without clinical or biochemical progression was 7 months. The median survival without the need for further systemic treatment was 9 months. During the follow-up period, six patients received second-generation hormone therapy to treat their relapse, and the other two showed no clinical or biochemical
